Medical and Health Science Journal

  Previous Article | Back to Volume | Next Article
  Abstract | References | Citation | Download | Preview | Statistics
Volume 8
Issue 4
Online publication date 2011-07-29
Title Direct efficiency of different modes of scheme “paclitaxel Caelyx” in the treatment of patients having inflammatory breast cancer
Author Suriya Yessentayeva, Nino Chichua, A. Khozhayev, Zhanna Mussakhanova, Ramil Abdrakhmanov, Bakir Kozhakhmetov, Gulnar Tleugabilova, Roza Abdulakhanova, Yu. Starchenko, K. Niyazbekova
Abstract Inflammatory breast cancer (IBC) with a poor prognosis occurs in 1-5% of patients with breast cancer. Combination of Paclitaxel  and Caelyx were applied for 42 patients with IBC with the use of 2 regimens. Paclitaxel  - 135 mg/m² 1 day, Caelyx  40 mg/m² 1day within a cycle of 3 weeks (21 sick women); the weekly regimen has a scheme: 60 mg/m² on 1st, 8th and15th days and Caelyx - 25 mg/m² on 1st, 8th days within a cycle of 4 weeks (21 sick women). The final analysis of the effectiveness of 2 chemotherapy regimens showed that an objective impact was reached in 85.7% (18/21) in the group of weekly insertion of the drugs by the end of the research; and in the group of routine chemotherapy it was 52.4% (11/21). Though general results are satisfactory in both 2 regimens of the chemotherapy, the weekly insertion of the drugs let to decrease a hematologic toxicity of 3-4 degree in 2.5-3 times and a frequency of LPS in 10 times.
Citation
References
Cristofanilli, M., Valero, V., Buzdar, A.U. et al., 2006. “Inflammatory breast cancer (IBC): Patterns of recurrence and micrometastatic homing,” Breast Cancer Res. Treat., Vol.100 (Suppl 1), p.155 

Hindenburgl, H., Hinke, A., John, M. et al., 2003. “Every week introduction of paclytaxel and herceptin to patients with metastatical inflammatory breast cancer - multi-center research in Germany,” Modern oncology, Vol.5, pp.56-61

Kurpeshev, O., Cyb, A., Mardynskiy, Y., Berdov, B., 2003. “Mechanisms of the development and the ways of overcoming of tumor chemoresistance,” Russian oncology magazine [Rossiiskii Onkologicheskii Jurnal], in Russian, Vol.2, pp.50-53

Liauw, S., Benda, R., Morris, C., Mendenhall, N., 2004. “Inflammatory breast carcinoma: Outcomes with trimodality therapy for nonmetastatic disease,” Cancer, Vol.100(5), pp.920-928

O’Brein, M., Wigler, N., Inbar, M. et al., 2004. “Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin versus conventional doxorubicin for first line treatment of metastatic breast cancer,” Ann.Oncol., Vol.15, pp.440-49

Perevodchikova, N., 2001. “The place of taxol in modern clinical practice” [Mesto taxola v sovremennoy klinicheskoy praktike], in Russian, in: Perevodchikova, N. (Ed.), Taxol in clinical practice

Seidman, A., Norton, L., Reichman, B. et al., 1999. ”Preliminary experience with Paclitaxel (Taxol) plus recombinant human granulocyte colony-stimu-lating factor in the treatment of breast cancer,” Semin. Oncol., Vol.20, pp.40-45

Somlo, G., Frankel, P., Chow, W. et al., 2004. ”Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy”. J Clin Oncol.,  No.2, pp.1839-848

Tai, P., Yu, E., Shiels, R. et al., 2005. “Short-and long-term cause-specific survival of patients with inflammatory breast cancer,” BMC Cancer, No.5, p.137

Keywords Inflammatory breast cancer, chemotherapy, paclitaxel, cael
Pages 9-15
Download Full PDF Download
  Previous Article | Back to Volume | Next Article
Share
Search in articles
Statistics
Journal Published articles
MHSJ 940
Journal Hits
MHSJ 2616038
Journal Downloads
MHSJ 17529
Total users online -